source
- Merck and Moderna’s melanoma vaccine shows positive Phase 3 results, boosting investor confidenceMerck and Moderna announced that their personalized melanoma vaccine met the primary endpoint of recurrence‑free survival in a Phase 3 trial when given together with Keytruda. The study showed pati…
- Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious diseaseEli Lilly has turned to one of its Gateway Labs residents to help the Big Pharma develop trans-amplifying RNA (taRNA) vaccines for infectious diseases.Fierce Biotech · 9h ago↗ source